Abrahamsson PA et al. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Eur Urol 2005;48(6):900-5. Abstract

Bolla M et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572-8. Abstract

Bolla M et al; European Organization for Research and Treatment of Cancer. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Denham JW et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6(11):841-50. Abstract

Eng TY et al. The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer. Curr Urol Rep 2005;6(3):194-209. Abstract

Hanks GE et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8. Abstract

Janoff DM et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 2005;96(4):503-7. Abstract

Kamat AM et al. Validation of criteria used to predict extraprostatic cancer extension: A tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 2005;174(4 Pt 1):1262-5. Abstract

Lawton CA et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800-7. Abstract

Park S et al. Androgen deprivation use with external beam radiation for prostate cancer: Results from CaPSURE. J Urol 2005;174(5):1802-7. Abstract

Penson DF. An update on randomized clinical trials in localized and locoregional prostate cancer. Urol Oncol 2005;23(4):280-8. Abstract

Pickett B et al. Comparing high dose external beam radiotherapy (EBRT) and permanent prostate implant (PPI) in treating low risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging (MRSI) and PSA. Proc ASCO Prostate 2005;Abstract 86.

Roach M 3rd et al. Predicting long-term survival, and the need for hormonal therapy: A metaanalysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47(3):617-27. Abstract

Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 2005;23(32):8225-31. Abstract

Salesi N et al. Prostate cancer: The role of hormonal therapy. J Exp Clin Cancer Res 2005;24(2):175-80. Abstract

Tyrrell CJ et al; ‘Casodex’ Early Prostate Cancer Trialists’ Group. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005;76(1):4-10. Abstract

Wirth MP et al; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70. Abstract

Yamanaka H et al. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 2005;63(1):56- 64. Abstract

Zhou P et al. Predictors of prostate cancerspecific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23(28):6992- 8. Abstract